Introduction
Polycythemia vera is the most common primary polycythemia with an estimated incidence of 2.3 per 100 000 persons per year [1, 2] . This myeloproliferative neoplasm is characterized by clonal proliferation of hematopoietic precursors that leads to an increased erythrocyte mass unrelated to erythropoietin (EPO) levels and increased platelet and granulocyte counts. Consequences include splenomegaly, hyperuricemia with secondary gout, erythromelalgia, neurological manifestations, aquagenic pruritus, hemorrhage, along with a long-term risk of evolution to myelofibrosis, myelodysplasia and acute leukemia. Thrombotic complications are the major cause of morbidity and mortality and are reported as the presenting symptom in 12-49% of patients [1, 2] . Deep venous thrombosis, acute coronary syndrome, Budd-Chiari syndrome, pulmonary embolism, stroke and transient ischemic attacks have been previously attributed to hyperviscosity from the increased hematocrit and/or thrombocytosis [3, 4] . However, these causes have recently been challenged [5, 6] and other contributing mechanisms likely exist. For example, the European Collaborative Study on Low-Dose Aspirin in Polycythemia Vera showed that the rate of major thrombotic events was approximately doubled in patients older than 65 years of age and was four-fold higher in individuals with an additional thrombotic history [7] . Leukocytosis has been reported as an independent risk factor for arterial thrombosis [5, 8, 9] . The presence of the JAK2 V617F mutation and/or the burden of mutated alleles have been associated with thrombotic complications in polycythemia vera [10, 11] even though a prospective study has not confirmed this finding [11] . Thus, the pathophysiology of thrombosis in polycythemia vera is not yet entirely explained.
Chronic hypoxia induces many physiological responses to compensate for the decreased tissue oxygen supply, including EPO production that may result in secondary erythrocytosis and pulmonary hypertension. Chuvash polycythemia, an autosomal recessive genetic disorder with augmented hypoxia sensing, shares features with both primary and secondary polycythemia. These patients are homozygous for the R200W loss-of-function mutation in the Von Hippel Lindau (VHL) tumor suppressor gene, a negative regulator of the alpha subunit of hypoxia inducible factors (HIFs) [2, 8] . Chuvash polycythemia patients have elevated HIF-1 and HIF-2 levels at normoxia resulting in increased EPO production and an elevated red blood cell mass; yet the mechanisms of augmented erythropoiesis are not fully explained [2, 8, 12] . Chuvash polycythemia is characterized by an increased morbidity and mortality largely due to thrombotic complications, which appear unrelated to the hematocrit level. These considerations suggest either that inherited augmented hypoxia-sensing or environmental extrinsic conditions could play a significant role in the pathogenesis of vascular complications in polycythemia vera [13] .
To our knowledge, environmental conditions have not been examined as potential modifying factors for the development of thrombotic events in cancer patients. Salt Lake City (SLC), Utah, is located in a valley at $5000 feet of altitude and surrounded by populated mountains reaching 9000 feet. This relatively hypoxic environment is appreciated by physiologic sensors and is reflected in a mean hemoglobin concentration that is 0.6-1.3 g/dl higher than the average value in the United States [14] . To analyze the effect of relative hypoxia on polycythemia vera-associated thrombosis, we retrospectively compared the prevalence of thrombotic complications in patients dwelling in SLC with those inhabiting at sea level in Baltimore (BLM), Maryland.
Patients and methods
We reviewed the clinical history of 237 polycythemia vera patients from 2005 to 2010. Seventy-one individuals inhabited the SLC area at an average elevation of $5000 feet above sea level or more, and 166 were living in the BLM area located at sea level. The diagnosis of polycythemia vera was based on the Polycythemia Vera Study Group and WHO Criteria and all patients were positive for JAK2 V617F mutation [15, 16, 17] . Genomic DNA was isolated from purified granulocytes using the Puregene DNA purification kit (Gentra, Minnesota, USA) in both BLM and Salt Lake City. The JAK2 V617F mutational burden in neutrophil genomic DNA was determined by a quantitative allele-specific polymerase chain reaction (AS-PCR) at both the University of Utah and at ARUP Laboratories (Salt Lake City) [18] , and by a quantitative real-time PCR assay using allele-specific probes in BLM [19] . The median time to diagnosis for JAK2 V617F mutational burden was 4.8 years in Salt Lake City, and 5.6 years in BLM (concordance of assays as in Ref. 20) [20] .
All patients signed an Institutional Review Boardapproved informed consent that indicated their medical records were available for our analysis. Collected information included: JAK2 allelic burden, thromboses history, age at first thrombosis, white blood cell (WBC) count, use of anticoagulant and/or antiplatelet therapy and type of thrombotic events. In this analysis, we considered all the following thrombotic event types: transient ischemic attack (TIA), acute coronary syndrome (ACS), cerebrovascular accident (CVA), deep venous thrombosis (DVT), pulmonary embolism, abdominal and sagittal vein thrombosis, miscarriage, and minor occlusive events, such as erythromelalgia.
Statistical analysis
Categorical variables were compared among groups by the X 2 test. Continuous numeric variables were expressed as medians and compared among groups by the Kruskall-Wallis test. Statistical significance was set at 0.05 (P < 0.05). The relationship of thrombosis history to study site was examined in univariate and multivariate logistic regression models.
Results
A total of 237 patients were included in this retrospective analysis, 71 from SLC and 166 from BLM ( Table 1 ). The SLC patients were predominantly men (68%) whereas those in BLM were predominantly women (64%). The SLC patients were older (mean age: 67 years) than the BLM patients (mean age: 53 years) (P < 0.0001). SLC cohort included: 65 whites and six Native Americans and Asians. BLM cohort included: 151 Caucasians, 11 Afro-Americans and four others. The median disease duration for patients at the time of our analysis was 7.8 years in SLC and 5.6 years in BLM. Over half of 
the patients in both cohorts (SLC and BLM) had received ASA but less than 25% had received warfarin with no significant difference between groups. The mean disease duration in SLC patients (7.8 years) was statistically longer (P ¼ 0.021) compared with the BLM polycythemia vera individuals (5.6 years). The WBC count of 11.7 Â 10 9 per litre in the SLC group was considerably lower than the count of 15.3 Â 10 9 per litre observed in the BLM group (P ¼ 0.003).
Eighty-six patients (36%) experienced a thrombotic event, 41 cases (58%) in SLC group and 45 cases (27%) in the BLM cohort (P < 0.0001) ( Table 1 ). The mean age at the first thrombotic event was similar between the two groups of patients (60 years in SLC versus 57 years in BLM) (P ¼ 0.3). Thrombotic complications were higher in the SLC cohort irrespective of the age distribution ( Fig. 1a Frequency.% P ¼ 0.048). The SLC patients also demonstrated a significantly lower WBC counts after adjusting for age, sex and disease duration (P ¼ 0.003).
All analyzed patients were carriers for JAK2 V617F mutation. The mean allele burden in the BLM cohort was 66% and it was statistically higher (P ¼ 0.0002) than in the SLC cohort (49%). We performed univariate and multivariate analysis of all the known predictive factors for thrombosis in the entire group of patients (Tables 3  and 4 ). In multivariate analysis age, location and sex were all found statistically significant, but the JAK2 allele burden was not associated with thrombosis in the entire polycythemia vera group and not appreciable different in the patients with or without thrombosis in either location (P ¼ 0.30).
As shown in Fig. 1b Table 5 . There were differences in rates of abdominal venous thromboses but no significant differences in the type of cardiovascular events between the two groups.
Discussion
Increased blood viscosity due to high hematocrit as well as quantitative and qualitative platelet and leukocyte abnormalities are considered to have a major role in the pathogenesis of the polycythemia vera-associated thrombophilia [1, 3, 4] . However, other major contributing factors to polycythemia vera thromboses still need to be delineated and one potential factor could be an augmented hypoxic signaling [21] . We investigated the possible role of relative hypoxia in the SLC area as one of the contributing factors to thromboses in polycythemia vera. We retrospectively analyzed two groups of polycythemia vera patients, one living in SLC at $5000 feet and more above sea level and another living in BLM close to sea level. Under hypoxic conditions, multiple physiologic compensatory mechanisms take place to adapt tissues to a lower oxygen partial pressure, including elevated EPO [2, 22, 23] . It is tempting to consider that hypoxia driven upregulation of HIF-family transcription factors could also be involved in the thrombotic tendency in polycythemia vera patients living at high altitudes despite the well documented suppression of EPO production in polycythemia vera. Consistent with other reports, we observe a considerable percentage of thrombotic events in both cohorts manifested before the diagnosis of polycythemia vera. In the prospective multicenter European Collaboration on Low-dose Aspirin in Polycythemia Vera study, 35.8% of patients developed a thrombotic event before and only 10% after enrollment [24] ; similar findings were reported in the Gruppo Italiano Studio Policitemia with a 22% incidence of major thromboses prior to diagnosis and a much lower incidence after polycythemia vera diagnosis was established [25] .
These reports resemble what we observed in the SLC cohort wherein a positive history of thrombotic events was documented in 58% of patients, of which 18% occured before polycythemia vera diagnosis (n ¼ 13). In the BLM cohort, the total rate of thromboses was overall markedly lower (27%) with only 4% of patients (n ¼ 7)
reporting thrombotic events before the diagnosis.
These findings suggested a possible role of relative hypoxia in the pathogenesis of thrombotic complications. Both the BLM and SLC cohorts consisted of entirely positive patients for JAK2 V617F mutation. The mean allele burden was higher in the BLM cohort (66%) than the SLC cohort (36%; P ¼ 0.0002). Although the presence of the mutation has been considered to be a cofactor for increasing the rate of thromboses [26] , our multivariate analysis failed to show any association of JAK2 with thrombosis in the entire group or in each separate cohort.
As leukocytosis has been previously described as an independent prothrombotic factor in polycythemia vera patients [8] , we analyzed its possible contribution in developing thrombosis among patients living in SLC.
In a multivariate analysis, we found a higher prevalence of thrombosis despite the considerably lower WBC count (11.7 Â 10 9 per litre) in SLC compared with the BLM cohort (15.3 Â 10 9 per litre) (P ¼ 0.003).
The reported male-to-female ratio in polycythemia vera is 1.2-2.2 [1, 27, 28] , in our study is more representative of the SLC region population. By univariate analysis, female sex was associated with an increased risk of abdominal vein thrombosis and in multivariate analysis female sex remained as an independent risk factor for the history of thrombosis. Previously in the literature [4] , and more recently by us [29] , a relationship between sex and thrombotic complications has been described. Interestingly, the BLM cohort mainly represented by women (64%), had a lower rate of thrombosis in comparison with the cohort in SLC. Our multivariate analysis of all the known prothrombotic factors in the entire group of patients suggested that location (SLC) was a prominent element indicating hypoxia as a possible driving factor in vascular complications developed by polycythemia vera patients.
In keeping with the suggestion from our data that even mild-to-moderate chronic hypoxia may be a contributing prothrombotic factor in polycythemia vera, the constitutive increase of hypoxia sensing due to upregulated levels of HIF-1 and HIF-2 in Chuvash polycythemia, produces the transcription of a myriad of HIF-1 and HIF-2 target genes including EPO, the transferrin receptor and VEGF. The condition is associated with a marked increase of thrombotic complications, which do not correlate with either with hemoglobin/hematocrit nor phlebotomy [13] . However, the serum EPO concentration was higher in 20 VHL R200W homozygotes from Chuvashia with a history of thrombosis than 72 homozygotes without a history of thrombosis: median and interquartile ranges of 37 (17-76) IU/l versus 59 (43-106) IU/l, respectively, P ¼ 0.03 (V. Gordeuk, unpublished data, 2012) . This potentially implicates EPO itself in the increased thrombotic risk.
It needs to be considered that there is a substantial individual variability in the response to hypoxia, making the ultimate outcome of effect of hypoxia unpredictable in an otherwise unselected individual [30] [31] [32] . These presumably genetic factors accounting for the variable hypoxic response remain to be defined. Some of these factors have been selected in certain populations, such as Tibetan and Andean highlanders [33] and their function is being currently elucidated [34] . Thus, the hypoxic exposure would be expected to result in varied activation of HIF-regulated pathways found in patients with heterogeneous genetic background as reported in US athletes [35] .
It is tempting to speculate that the different levels of HIF activation in a hypoxic environment may correlate with the diverse thrombotic risk encountered in polycythemia vera patients. The possible mechanisms of augmented thrombotic risks in moderate hypoxic environment include differences in EPO levels or an augmentation of yet to be defined HIF-regulated gene(s) with thrombophilic potential; however, future prospective studies and translational research will be needed to test the molecular basis substantiating our observation reported here. 
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